Thursday, 5 November 2026European Markets

GLANBIA PLC, GREENYARD, Another 1 Companies Have A High Dividend Yield And Return On Equity In The Consumer Defensive Sector.

Loading stream...

(VIANEWS) - GLANBIA PLC (GL9.IR) is among this list of stock assets with the highest dividend rate and return on equity on the Consumer Defensive sector.

Financial Asset Price Forward Dividend Yield Return on Equity
GLANBIA PLC (GL9.IR) €18.60 1.95% 16.86%
GREENYARD (GREEN.BR) €5.76 1.69% 3.12%
KERRY GROUP PLC (KRZ.IR) €79.25 1.53% 11.42%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. GLANBIA PLC (GL9.IR)

1.95% Forward Dividend Yield and 16.86% Return On Equity

Glanbia plc, together with its subsidiaries, operates as a nutrition company worldwide. The company offers sports nutrition and lifestyle nutrition products in various formats, such as powders, ready-to-eat bars and snacking food, and ready-to-drink beverage. It also manufactures and sells cheese, dairy, and non-dairy nutritional and functional ingredients; and vitamin and mineral premixes products. In addition, the company engages in the financing; research and development; property and land dealing; holding and management of receivables; property leasing; business services; management solutions; weight management; flavor solutions; and bioactive solutions businesses. It offers its products under the Optimum Nutrition, BSN, Isopure, Nutramino, SlimFast, think!, Amazing Grass, Body & Fit, and LevlUp brands. The company sells its products through specialty retail, online, gym, and food, drug, mass, and club channels. Glanbia plc was founded in 1964 and is headquartered in Kilkenny, Ireland.

Earnings Per Share

As for profitability, GLANBIA PLC has a trailing twelve months EPS of €1.19.

PE Ratio

GLANBIA PLC has a trailing twelve months price to earnings ratio of 15.63. Meaning, the purchaser of the share is investing €15.63 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.86%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GLANBIA PLC's stock is considered to be oversold (<=20).

Volatility

GLANBIA PLC's last week, last month's, and last quarter's current intraday variation average was a positive 0.18%, a negative 0.14%, and a positive 0.70%.

GLANBIA PLC's highest amplitude of average volatility was 0.37% (last week), 0.63% (last month), and 0.70% (last quarter).

Yearly Top and Bottom Value

GLANBIA PLC's stock is valued at €18.60 at 07:30 EST, below its 52-week high of €19.20 and way above its 52-week low of €13.30.

More news about GLANBIA PLC.

2. GREENYARD (GREEN.BR)

1.69% Forward Dividend Yield and 3.12% Return On Equity

Greenyard NV, together with its subsidiaries, supplies fresh, frozen, and prepared fruit and vegetables, flowers, and plants in Germany, the Netherlands, Belgium, the United Kingdom, France, the rest of Europe, and internationally. The company operates through Fresh and Long Fresh segments. The Fresh segment markets and supplies fresh fruit and vegetables, flowers and plants, and fresh produce logistics. Its Long Fresh segment processes freshly harvested fruits and vegetables into frozen food products; and offers freshly preserved fruit, vegetables, and other ambient food products, as well as ready-made products, such as soups, sauces, dips, and pasta dishes. The company was formerly known as Greenyard Foods NV and changed its name to Greenyard NV in September 2016. Greenyard NV was founded in 1965 and is based in Sint-Katelijne-Waver, Belgium.

Earnings Per Share

As for profitability, GREENYARD has a trailing twelve months EPS of €0.28.

PE Ratio

GREENYARD has a trailing twelve months price to earnings ratio of 20.57. Meaning, the purchaser of the share is investing €20.57 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.12%.

More news about GREENYARD.

3. KERRY GROUP PLC (KRZ.IR)

1.53% Forward Dividend Yield and 11.42% Return On Equity

Kerry Group plc, together with its subsidiaries, provides taste and nutrition solutions. The company operates in two segments, Taste & Nutrition, and Dairy Ireland. The Taste & Nutrition segment offers taste and nutrition solutions for the food, beverage, and pharmaceutical markets. The Dairy Ireland segment provides value-add dairy ingredients and consumer products, including functional proteins and nutritional bases. It operates in Ireland, rest of Europe, the Americas, the Asia Pacific, the Middle East, and Africa. Kerry Group plc was founded in 1972 and is headquartered in Tralee, Ireland.

Earnings Per Share

As for profitability, KERRY GROUP PLC has a trailing twelve months EPS of €4.1.

PE Ratio

KERRY GROUP PLC has a trailing twelve months price to earnings ratio of 19.33. Meaning, the purchaser of the share is investing €19.33 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.42%.

More news about KERRY GROUP PLC.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com